Business Context and Reporting Period
This Form 8-K Current Report, dated December 3, 2009, is filed by Targacept, Inc. (noting the metadata reference to Gyre Therapeutics appears to be a discrepancy as the filing explicitly names Targacept). The report details the entry into a Material Definitive Agreement with AstraZeneca AB regarding the global development and commercialization of TC-5214, a product candidate for major depressive disorder. The agreement's effectiveness is contingent upon the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act).
Key Financial Metrics and Agreement Terms
The Collaboration Agreement outlines significant potential financial inflows for Targacept, though no historical revenue or profit data is provided in this specific filing.
- Upfront Payment: AstraZeneca is obligated to make a non-refundable upfront payment of $200,000,000 upon the agreement's effectiveness.
- Development and Regulatory Milestones: Targacept is eligible to receive up to an additional $540,000,000 upon achieving specified development, regulatory, and first commercial sale milestones.
- Sales Milestones: Targacept is eligible for up to an additional $500,000,000 based on specified sales-related milestones.
- Royalties: The agreement provides for significant stepped double-digit royalties on net sales following regulatory approval.
- Cost Sharing: AstraZeneca is responsible for 80% of the initial global clinical program costs, while Targacept is responsible for 20%. Targacept has the right to defer its share of costs exceeding a specified threshold, recoverable from future milestones and royalties.
- Third-Party Obligations: Targacept must pay a percentage of the upfront and milestone payments, as well as royalties, to the University of South Florida Research Foundation and Yale University. The effective worldwide royalty rate is expected to be in the low single digits, potentially reaching mid-single digits.
Material Changes and Strategic Developments
The primary material change is the execution of the Collaboration Agreement, which grants AstraZeneca an exclusive global license to develop and commercialize TC-5214 for all fields of use except hypertension. Additionally, Targacept entered into an Amended and Restated Supply Agreement with Poli Industria Chimica, S.P.A. and Interchem Corporation for the manufacturing of the active pharmaceutical ingredient (TC-5214 API). Targacept has agreed to assign this supply agreement to AstraZeneca upon the Collaboration Agreement's effectiveness.
Guidance, Outlook, Risks, and Contingencies
Outlook and Timeline: The companies anticipate beginning a Phase 3 clinical development program in mid-2010, with a goal of submitting a New Drug Application (NDA) in 2012. AstraZeneca will handle global commercialization, with Targacept retaining an option to co-promote in the U.S.
Regulatory Risks: TC-5214 is a single enantiomer of a previously approved racemate. To qualify for five years of marketing exclusivity as a new chemical entity, an NDA must be submitted prior to October 1, 2012. Failure to meet this deadline or statutory conditions would limit exclusivity to three years, increasing reliance on patent protection.
Patent Expiration: U.S. patent rights expire between 2017 and 2020, with foreign patents expiring between 2017 and 2019. Pending applications could extend protection to 2030 if issued.
Termination Rights: AstraZeneca may terminate the agreement if HSR clearances are not obtained by March 1, 2010, or based on safety issues, patent infringement risks, or after the Phase 3 program. Targacept may terminate if AstraZeneca challenges the validity of licensed patents.
Key Facts for Investor Verification
- Confirmation of the HSR Act waiting period expiration to trigger the $200 million upfront payment.
- Verification of the specific royalty percentages payable to the University of South Florida Research Foundation and Yale University.
- Assessment of the risk regarding the October 1, 2012, deadline for NDA submission to secure five-year marketing exclusivity.
- Review of the status of pending patent applications critical to extending the royalty term beyond 2020.
- Confirmation of AstraZeneca's assumption of the supply agreement obligations with Poli Industria Chimica.